The KRAS-variant and its impact on normal breast epithelial cell biology
Song-yi Jung, Poonam Malhotra, Kiana C Nguyen, David Salzman, Yue Qi, Ethan H Pak, Joshua King, Erina Vlashi, David Ann, Joanne B Weidhaas Cell Death & Differentiation 26 (12), 2568-2576
A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy.
Joanne B Weidhaas, Aaron Wolfe Scheffler, David Salzman, Anusha Kalbasi, Kirk Wilenius, Emily Rietdorf, Mara Heilig, Mattias Pitka, Caroline Desler, Dan Ruan, Antoni Ribas, Alexandra Drakaki, Mark C Scholz, Donatello Telesca Journal of Clinical Oncology 37 (8_suppl), 96-96
Identification of Biomarkers for Early-Detection and Monitoring of Huntington Disease
DW Salzman, J Bregu, NS Ray, RH Myers NEUROTHERAPEUTICS 15 (4), 1213-1214
Germ-line biomarkers disrupting microRNA regulatory pathways to predict toxicity and response to anti-PD-1 and anti-PD-L1 therapies.
JB Weidhaas, D Telesca, A Kalbasi, D Salzman, A Ribas Journal of Clinical Oncology 35 (15_suppl), 3040-3040
miR-34 activity is modulated through 5′-end phosphorylation in response to DNA damage
David W Salzman, Kotoka Nakamura, Sunitha Nallur, Michelle T Dookwah, Chanatip Metheetrairut, Frank J Slack, Joanne B Weidhaas Nature communications 7 (1), 1-9
Estrogen withdrawal, increased breast cancer risk and the KRAS-variant
Terri P McVeigh, Song-Yi Jung, Michael J Kerin, David W Salzman, Sunitha Nallur, Antonio A Nemec, Michelle Dookwah, Jackie Sadofsky, Trupti Paranjape, Olivia Kelly, Elcie Chan, Nicola Miller, Karl J Sweeney, Daniel Zelterman, Joann Sweasy, Robert Pilarski, Donatello Telesca, Frank J Slack, Joanne B Weidhaas Cell Cycle 14 (13), 2091-2099
A germline mutation in the BRCA13’UTR predicts Stage IV breast cancer
Jemima J Dorairaj, David W Salzman, Deirdre Wall, Tiffany Rounds, Carina Preskill, Catherine AW Sullivan, Robert Lindner, Catherine Curran, Kim Lezon-Geyda, Terri McVeigh, Lyndsay Harris, John Newell, Michael J Kerin, Marie Wood, Nicola Miller, Joanne B Weidhaas BMC cancer 14 (1), 1-11
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy
Zenia Saridaki, Joanne B Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, Sabine Tejpar Clinical Cancer Research 20 (17), 4499-4510
SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer
DW Salzman, JB Weidhaas Pharmacology & therapeutics 137 (1), 55-63
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
Amy J Wegener, Amy Setnicka, Kathleen M Schoch, Mariah L Hoye, Mark Shabsovich, Timothy M Miller Washington University School of Medicine OPEN ACCESS PUBLICATIONS
